Ultragenyx Pharma (RARE) Announces Presentations Highlighting KRN23 at ASBMR Meeting

August 23, 2016 8:38 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced upcoming presentations of data highlighting KRN23 for the treatment of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO) at the American Society for Bone and Mineral Research (ASBMR) 2016 Annual Meeting taking place September 16-19 in Atlanta, Georgia.

Two oral presentations will highlight 40-week (n=52) and 64-week (n=36) data from the Phase 2 pediatric XLH study, as well as results from the ongoing Phase 2 TIO study:

Oral Presentation #1154: A Randomized, Open-label Phase 2 Study of KRN23, a Fully Human Anti-FGF23 Monoclonal Antibody, in 52 Children with X-linked Hypophosphatemia (XLH)

  • Monday, September 19, 9:45 - 10:00 AM ET
  • Room 412, Georgia World Congress Center

Oral Presentation #1098: Effects of KRN23, an Anti-FGF23 Antibody, in Patients With Tumor Induced Osteomalacia and Epidermal Nevus Syndrome: Results from an Ongoing Phase 2 Study

  • Sunday, September 18, 10:15 - 10:30 AM ET
  • Sidney Marcus Auditorium, Georgia World Congress Center

Posters highlight additional KRN23 data including functional patient-reported outcomes from the Phase 2 pediatric XLH study, and data from the open-label extension study in adults with XLH:

Poster #FR0331 and #SA0331 (shown twice): Evaluating the Effects of KRN23, a Fully Human Anti-FGF23 Monoclonal Antibody, on Functional Outcomes in Children with X-linked Hypophosphatemia (XLH): 40-week Interim Results from a Randomized, Open-label Phase 2 Study

  • Friday, September 16, 5:30 - 7:00 PM ET and Saturday, September 17, 12:30 – 2:30 PM ET
  • ASBMR Discovery Hall - Expo Hall A1, Georgia World Congress Center

Poster #MO0319: Clinical and Radiographic Characteristics of Adult X-linked Hypophosphatemia (XLH) in a Cohort of Patients Treated with KRN23, an Antibody to FGF23

  • Monday, September 19, 12:30 - 2:30 PM ET
  • ASBMR Discovery Hall - Expo Hall A1, Georgia World Congress Center



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, FDA

Add Your Comment